💥 Drug discovery software is broken Customers pay big fees for tools that may not work 👉🏽 We started KlyneAI to build tailored tools for your challenges—not generic ones No sugar-coating. If it doesn’t work, we stop—you don’t waste money.Time for an honest, problem-driven approach to drug discovery

Check out this hot take from our CTO 👇 At Klyne, we focus on practical, results-driven drug discovery—for most clients, ultra-large virtual screening (trillions of compounds 🌐) makes sense with conventional docking. It’s fast, scalable, and gets the job done Curious to learn more? [klyne@klyne.ai]

Akshat Nigam@akshatai.bsky.social · last yr.

Hot take in drug discovery: The real value of molecular docking lies in ranking for (ultra-large) virtual screening. Structure co-folding models with ligands? Super cool! But unless they prove themselves in screening performance, conventional docking still wins 🤔

🚀 Big news from Klyne! We’re thrilled to be collaborating with @cgorgulla.bsky.social ky.social's lab to develop the next generation of tools for accelerating drug discovery. Stay tuned—some exciting papers are on the way from this collaboration!

🚀 Exciting News! 🚀 KlyneAI is thrilled to join JLABS! We’re pushing the boundaries of biotech innovation and developing cutting-edge tools for drug discovery. Want to collaborate on AI-driven drug discovery? → klyne@klyne.ai #Biotech #DrugDiscovery #AI #JLabs (Yes, the view’s amazing) 🤩

Check out this great interview with the incredible @aspuru.bsky.social on BNNBloomberg, highlighting a recent publication co-authored by our CTO, @akshatai.bsky.social ! [Paper: rdcu.be/d68Fs] Exciting times ahead for Klyne—stay tuned for more! 🚀🔬 t.co/tkLsgjcSDb

🚀 Big news from Klyne! Check out our CTO’s work—the first quantum generative model for hit discovery! At Klyne, we build affordable tools for drug discovery: ✨ Pay-as-you-go (no licensing fees, ~10x cheaper) 💡 Expert team for every stage 📩 [klyne@klyne.ai]

Akshat Nigam@akshatai.bsky.social · 2y ago

Excited to share our latest work, published this morning in Nature Biotechnology! 🎉 We developed a hybrid quantum computing-enhanced generative model to design KRAS inhibitors. Check it out here: rdcu.be/d68Fs. Some fascinating insights along the way:

Thrilled to welcome @akshatai.bsky.social to Klyne! 🚀 Stay tuned for exciting science updates. Have biotech questions or needs? We're here to help: klyne@klyne.ai

Akshat Nigam@akshatai.bsky.social · 2y ago

Excited to share some news this New Year! I’ll be joining @klyneai.bsky.social as CTO soon. We co-founded Klyne to revolutionize biotech with cost-effective, no-licensing-fee software solutions. 🚀 If you're interested in screening, hit optimization, or FEP calculations, reach out: klyne@klyne.ai 😉